Fernwood Investment Management LLC Continues to Hold Stake in Danaher Corporation (DHR)
Fernwood Investment Management LLC maintained its stake in shares of Danaher Corporation (NYSE:DHR) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,436 shares of the conglomerate’s stock at the end of the first quarter. Fernwood Investment Management LLC’s holdings in Danaher Corporation were worth $294,000 at the end of the most recent quarter.
Several other large investors have also recently modified their holdings of DHR. Parnassus Investments CA boosted its position in shares of Danaher Corporation by 15.3% in the first quarter. Parnassus Investments CA now owns 8,622,528 shares of the conglomerate’s stock worth $712,738,000 after buying an additional 1,143,284 shares during the period. Bank of New York Mellon Corp boosted its position in shares of Danaher Corporation by 0.7% in the first quarter. Bank of New York Mellon Corp now owns 7,645,818 shares of the conglomerate’s stock worth $653,946,000 after buying an additional 50,673 shares during the period. Norges Bank acquired a new position in shares of Danaher Corporation during the fourth quarter worth $465,363,000. Dodge & Cox acquired a new position in shares of Danaher Corporation during the fourth quarter worth $406,424,000. Finally, Flossbach Von Storch AG boosted its position in shares of Danaher Corporation by 6.2% in the first quarter. Flossbach Von Storch AG now owns 3,996,209 shares of the conglomerate’s stock worth $341,796,000 after buying an additional 234,770 shares during the period. Institutional investors and hedge funds own 76.22% of the company’s stock.
Danaher Corporation (DHR) traded down 0.33% during midday trading on Friday, reaching $81.01. 2,425,291 shares of the company traded hands. The company has a market cap of $56.28 billion, a price-to-earnings ratio of 25.86 and a beta of 1.03. Danaher Corporation has a 12-month low of $75.71 and a 12-month high of $88.01. The company has a 50-day moving average price of $83.93 and a 200-day moving average price of $84.29.
Danaher Corporation (NYSE:DHR) last announced its earnings results on Thursday, July 20th. The conglomerate reported $0.99 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.97 by $0.02. Danaher Corporation had a return on equity of 11.15% and a net margin of 12.63%. The company had revenue of $4.51 billion during the quarter, compared to analyst estimates of $4.50 billion. During the same period last year, the company posted $0.90 earnings per share. The firm’s quarterly revenue was up 6.3% compared to the same quarter last year. On average, analysts predict that Danaher Corporation will post $3.95 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which was paid on Friday, July 28th. Stockholders of record on Friday, June 30th were paid a $0.14 dividend. The ex-dividend date was Wednesday, June 28th. This represents a $0.56 dividend on an annualized basis and a dividend yield of 0.69%. Danaher Corporation’s dividend payout ratio (DPR) is presently 17.83%.
ILLEGAL ACTIVITY NOTICE: This report was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.thecerbatgem.com/2017/08/04/danaher-corporation-dhr-position-held-by-fernwood-investment-management-llc-updated-updated-updated.html.
A number of research analysts have recently commented on DHR shares. Zacks Investment Research cut shares of Danaher Corporation from a “hold” rating to a “sell” rating in a research report on Monday, June 19th. Deutsche Bank AG reissued a “buy” rating and set a $97.00 target price on shares of Danaher Corporation in a research report on Wednesday, June 21st. BTIG Research reaffirmed a “buy” rating and issued a $92.00 price target on shares of Danaher Corporation in a report on Sunday, April 23rd. Vetr raised shares of Danaher Corporation from a “buy” rating to a “strong-buy” rating and set a $94.18 price target on the stock in a report on Thursday, April 20th. Finally, Wells Fargo & Company initiated coverage on shares of Danaher Corporation in a research note on Thursday, July 13th. They set a “market perform” rating and a $90.00 target price for the company. One analyst has rated the stock with a sell rating, three have assigned a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $91.76.
In related news, Director Linda P. Hefner sold 10,578 shares of Danaher Corporation stock in a transaction dated Friday, July 21st. The stock was sold at an average price of $83.03, for a total value of $878,291.34. Following the completion of the sale, the director now directly owns 42,151 shares in the company, valued at $3,499,797.53. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Angela S. Lalor sold 10,815 shares of the firm’s stock in a transaction dated Tuesday, May 23rd. The stock was sold at an average price of $84.16, for a total value of $910,190.40. Following the transaction, the senior vice president now owns 39,020 shares in the company, valued at approximately $3,283,923.20. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 38,623 shares of company stock valued at $3,206,426. 12.20% of the stock is currently owned by corporate insiders.
About Danaher Corporation
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Receive News & Stock Ratings for Danaher Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher Corporation and related stocks with our FREE daily email newsletter.